orkambi 200 mg 125 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.
orkambi 200 mg 125 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.
orkambi 200 mg 125 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.
orkambi 200 mg 125 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation
orkambi 200 mg 125 mg film coated tabltes
vertex pharmaceuticals (u.k) limited, israel - ivacaftor; lumacaftor - film coated tablets - ivacaftor 125 mg; lumacaftor 200 mg - ivacaftor and lumacaftor - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 12 years and older who are homozygous for the f508del mutation in the cftr gene.if the patient's genotype is unknown, cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene.limitations of usethe efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation.
kalydeco 150 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor - film coated tablets - ivacaftor 150 mg - ivacaftor - kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (cf) aged 6 years and older and weighing 25 kg or more who have one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data. limitations of use : kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene.
kalydeco 150 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor - film coated tablets - ivacaftor 150 mg - ivacaftor - kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (cf) aged 6 years and older and weighing 25 kg or more who have one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r.limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene
kalydeco 150 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor - film coated tablets - ivacaftor 150 mg - ivacaftor - kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (cf) aged 6 years and older and weighing 25 kg or more who have one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r.limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene
kalydeco 150 mg film coated tablets
vertex pharmaceuticals (u.k) limited, israel - ivacaftor - film coated tablets - ivacaftor 150 mg - ivacaftor - kalydeco tablets are indicated for the treatment of patients with cystic fibrosis (cf) aged 6 years and older and weighing 25 kg or more who have one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r.limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene
kalydeco 50 mg granules
vertex pharmaceuticals (u.k) limited, israel - ivacaftor - granules - ivacaftor 50 mg - ivacaftor - kalydeco granules are indicated for the treatment of children with cystic fibrosis (cf) aged 2 years and older and weighing less than 25 kg who have one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data. limitations of use:kalydeco is not effective in patients with cf who are homozygous for the f508del mutation in the cftr gene.